JP2018513155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513155A5 JP2018513155A5 JP2017553926A JP2017553926A JP2018513155A5 JP 2018513155 A5 JP2018513155 A5 JP 2018513155A5 JP 2017553926 A JP2017553926 A JP 2017553926A JP 2017553926 A JP2017553926 A JP 2017553926A JP 2018513155 A5 JP2018513155 A5 JP 2018513155A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- composition
- patient
- administered
- hrg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000048238 Neuregulin-1 Human genes 0.000 claims description 32
- 108090000556 Neuregulin-1 Proteins 0.000 claims description 32
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 32
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 238000009121 systemic therapy Methods 0.000 claims description 13
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
- 229960003668 docetaxel Drugs 0.000 claims description 6
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 6
- 229960005079 pemetrexed Drugs 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 238000003757 reverse transcription PCR Methods 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 238000007901 in situ hybridization Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 238000005549 size reduction Methods 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000002250 progressing effect Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149271P | 2015-04-17 | 2015-04-17 | |
| US62/149,271 | 2015-04-17 | ||
| PCT/US2016/027933 WO2016168730A1 (en) | 2015-04-17 | 2016-04-15 | Combination treatments with seribantumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513155A JP2018513155A (ja) | 2018-05-24 |
| JP2018513155A5 true JP2018513155A5 (cg-RX-API-DMAC7.html) | 2019-05-23 |
Family
ID=55854801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553926A Withdrawn JP2018513155A (ja) | 2015-04-17 | 2016-04-15 | セリバンツマブを用いた併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160303232A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3283068A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018513155A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170137886A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107750165A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016248329A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2983008A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201792294A1 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1248539A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL255092A0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA45420A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201708491PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016168730A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| WO2017161009A1 (en) * | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising targeted antibodies uses and methods of treatment |
| AU2018211985B2 (en) * | 2017-01-26 | 2025-02-13 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
| CN112654363A (zh) | 2018-07-09 | 2021-04-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
| KR20230109668A (ko) | 2020-11-16 | 2023-07-20 | 서로젠 오퍼레이팅, 인크. | 간-특이적 Wnt 신호 증강 분자 및 그의 용도 |
| CN115976196B (zh) * | 2022-12-16 | 2024-12-06 | 深圳市人民医院 | ErbB3作为肺动脉高压生物标志物和治疗靶点的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2592177A1 (en) * | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| EP2711434B1 (en) | 2005-06-20 | 2016-09-14 | Advanced Cell Diagnostics, Inc. | Multiplex detection of nucleic acids |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| AU2009281721A1 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
| SG183532A1 (en) | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| ES2674567T3 (es) | 2010-05-21 | 2018-07-02 | Merrimack Pharmaceuticals, Inc. | Proteínas de fusión biespecíficas |
| US9011863B2 (en) * | 2010-07-09 | 2015-04-21 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
| WO2012103341A1 (en) | 2011-01-27 | 2012-08-02 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid stage tumors using anti-erbb3 antibodies |
| BR112013022882A2 (pt) | 2011-03-11 | 2016-12-20 | Merrimack Pharmaceuticals Inc | uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários |
| US20150231238A1 (en) * | 2011-03-15 | 2015-08-20 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to erbb pathway inhibitors |
| JP2014527035A (ja) * | 2011-06-30 | 2014-10-09 | メリマック ファーマシューティカルズ インコーポレーティッド | 婦人科悪性腫瘍を治療するためのパクリタキセルとの組み合わせの抗ＥｒｂＢ３抗体 |
| AU2012294326A1 (en) | 2011-08-10 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy |
| AU2013201584A1 (en) | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
| WO2015048793A2 (en) * | 2013-09-30 | 2015-04-02 | Daiichi Sankyo Co., Ltd. | Nucleic acid biomarker and use thereof |
| EP3087394A2 (en) * | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
-
2016
- 2016-04-15 EP EP16718955.4A patent/EP3283068A1/en not_active Withdrawn
- 2016-04-15 SG SG11201708491PA patent/SG11201708491PA/en unknown
- 2016-04-15 CN CN201680035146.7A patent/CN107750165A/zh active Pending
- 2016-04-15 CA CA2983008A patent/CA2983008A1/en not_active Abandoned
- 2016-04-15 WO PCT/US2016/027933 patent/WO2016168730A1/en not_active Ceased
- 2016-04-15 HK HK18108183.0A patent/HK1248539A1/zh unknown
- 2016-04-15 KR KR1020177033074A patent/KR20170137886A/ko not_active Withdrawn
- 2016-04-15 EA EA201792294A patent/EA201792294A1/ru unknown
- 2016-04-15 MA MA045420A patent/MA45420A/fr unknown
- 2016-04-15 AU AU2016248329A patent/AU2016248329A1/en not_active Abandoned
- 2016-04-15 JP JP2017553926A patent/JP2018513155A/ja not_active Withdrawn
- 2016-04-15 HK HK18110002.5A patent/HK1250626A1/zh unknown
- 2016-05-17 US US15/156,603 patent/US20160303232A1/en not_active Abandoned
-
2017
- 2017-10-17 IL IL255092A patent/IL255092A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513155A5 (cg-RX-API-DMAC7.html) | ||
| RU2017125053A (ru) | Терапевтические, диагностические и прогностические способы для рака мочевого пузыря | |
| Srinivasan et al. | Head and Neck | |
| Arrondeau et al. | LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Non–Small-Cell Lung Cancer | |
| Guigay et al. | Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance | |
| Shah et al. | Head and neck | |
| Kumar et al. | Head and neck | |
| Tan et al. | P3. 02b-117 Phase Ib Results from a Study of Capmatinib (INC280)+ EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Topic: EGFR RES | |
| Singh et al. | Gefitinib plus docetaxel in non-small-cell lung cancer | |
| Laughlin et al. | Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer | |
| Ya | 464P apatinib (YN968D1) in performance status 2 or 3 patients with EGFR wild-type metastatic non-small cell lung cancer (NSCLC): a single-arm phase II study | |
| Hockings et al. | Low pass whole genome sequencing can be used to calculate the relative proportion of chemotherapy resistant disease in high grade serous ovarian cancer | |
| JP2019508032A5 (cg-RX-API-DMAC7.html) | ||
| Peng et al. | MA14. 01 Clinical and Genomic Features of Chinese Lung Cancer Patients with Germline Mutations | |
| Reni | Evidences and opinions for adjuvant therapy in pancreatic cancer | |
| Gupta et al. | Head and Neck | |
| Lim et al. | 65: Maintenance pemetrexed for non-squamous non-small cell lung cancer (NSCLC):‘real life’outcomes from a UK centre | |
| Sun et al. | 466P Gefitinib retreatment beyond progression in advanced NSCLC patients with sensitive EGFR mutations | |
| Das et al. | Head and neck | |
| Voon | Skin toxicity in an elderly patient: case report | |
| Petrelli et al. | 9126 POSTER Anaemia Risk With Anti-EGFR Agents in Advanced Non Small Cell Lung Cancer–a Meta-analysis of 10 Trials | |
| Pujari et al. | Head and Neck | |
| Grigorescu | 9127 POSTER Phase II Study of Eriotinib Plus Gemcitabine in First Line Treatment of Poor Prognosis (ECOG PS 2) Advanced Non-small Cell Lung Cancer Patients | |
| Raturi et al. | Head and Neck | |
| Aarthi et al. | Head and Neck |